-
Press Release
Novartis receives positive CHMP opinion for Cosentyx® in adolescents aged 12+ with hidradenitis suppurativa (HS)
-
Press Release
New long-term Rhapsido® (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)
-
Press Release
Novartis ianalumab two-year data at ACR show further improvements in Sjögren’s disease activity
-
Press Release
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)
-
Press Release
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
-
Press Release
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
-
Press Release
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
-
Press Release
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
-
Press Release
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
-
Press Release
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
-
Press Release
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
-
Press Release
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria